Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status

P Hofman*1,2,3,6, C Butori1,2,3, K Havet3, Y Hofman1,2,3, E Selva3, N Guevara4, J Santini4 and E Van Obbergen-Schilling*5,6

1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; 2INSERM ERI-21, Faculty of Medicine, University of Nice – Sophia Antipolis, Nice, France; 3Tissue Biobank Unit, Pasteur Hospital, Nice, France; 4Department of Oto-Rhino-Laryngology, Pasteur Hospital, Nice, France; 5Institute of Signaling, Developmental Biology and Cancer Research UMR CNRS 6543, Centre Antoine Lacassagne, Nice, France

Cortactin is an actin-binding Src substrate involved in cell motility and invasion. In this study, we sought to examine the prognostic importance of cortactin protein expression in head and neck squamous cell carcinoma (HNSCC). To do so, cortactin and EGF receptor (EGFR) expression was retrospectively evaluated by immunohistochemistry in a tissue microarray composed of 176 HNSCCs with a mean follow-up time of 5 years. Cortactin immunoreactivity was weak to absent in normal epithelial tissue. Overexpression of the protein in 77 out of 176 tumours (44%) was associated with more advanced tumour-node-metastasis stage and higher histologic grade. Cortactin overexpression was associated with significantly increased local recurrence rates (49 vs 28% for high and low expressing carcinomas, respectively), decreased disease-free survival (17 vs 61%), and decreased the 5-year overall survival of (21 vs 58%), independently of the EGFR status. In multivariate analysis, cortactin expression status remained an independent prognostic factor for local recurrence, disease-free survival, and overall survival. Importantly, we identified a subset of patients with cortactin-overexpressing tumours that displayed low EGFR levels and a survival rate that equalled that of patients with tumoral overexpression of both EGFR and cortactin. These findings identify cortactin as a relevant prognostic marker and may have implications for targeted therapies in patients with HNSCC.

British Journal of Cancer (2008) 98, 956–964. doi:10.1038/sj.bjc.6604245 www.bjcancer.com

© 2008 Cancer Research UK

Keywords: cortactin; head and neck squamous cell carcinoma; prognosis; EGF receptor; tissue microarray

Despite recent advances in cancer treatment, the 5-year overall survival rate for patients with squamous cell carcinoma of the head and neck (HNSCC) has not improved over the last 30 years (Forastiere et al, 2001; Greenlee et al, 2001). The primary cause of treatment failure in patients with early-stage disease is the development of second primary tumours, whereas patients who present with locally advanced disease are at risk for local–regional recurrence and metastasis, even with the use of near-tolerance doses of radiation (Day and Blot, 1992). Most of the current prognostic factors (such as tumour-node-metastasis (TNM) staging, surgical margin status, and perineural invasion) fail to provide definitive information regarding the biological behaviour of the tumour and its potential to recur. Thus, identifying a biological marker that correlates with recurrence would provide more accurate information on prognosis and enable the treating physician to select a more aggressive course of therapy for high-risk patients. Such a marker could also potentially serve as a target for drugs designed to seek out and exploit specific molecular defects in cancerous cells.

Tumour cell motility is required for local–regional invasion and metastasis. Motility is initiated by protrusion of the leading edge of the cell, resulting in the production of polarised lamellipodia oriented towards the direction of movement (Yamaguchi and Condeelis, 2007). Cortactin is a ubiquitously expressed Src substrate that engages in several protein–protein interactions that may be functionally relevant to tumoral progression. It accumulates in lamellipodia of motile cells where it plays a crucial role in the dynamic regulation of the actin cytoskeleton by virtue of its binding to filamentous (F) actin, Arp2/3, and components of the cortical actin-polymerising machinery (Weed and Parsons, 2001; Daly, 2004). Cortactin also colocalises with F-actin in invadopodia of metastatic tumour cells, where it participates in degradation of the extracellular matrix around tumours (Artym et al, 2006; Yamaguchi et al, 2006). The cortactin gene CTTN (formerly EMS1) resides on chromosome locus 11q13 that is frequently amplified in

*Correspondence: Dr E Van Obbergen-Schilling, Institute of Signaling, Developmental Biology and Cancer Research UMR CNRS 6543, Centre Antoine Lacassagne, 33 Avenue de Valombrose, Nice 06189, France; E-mail: vanobber@unice.fr and Professor P Hofman, INSERM ERI-21, Faculty of Medicine, Avenue de Valombrose, Nice 06107, France; E-mail: hofman.p@chu-nice.fr

6These authors contributed equally to this work.

Received 30 October 2007; revised 9 January 2008; accepted 14 January 2008; published online 12 February 2008
human cancers, including over 30% HNSCCs (Brookes et al., 1993; Schuurting, 1995; Huang et al., 2006; Gibcus et al., 2007). Thus, the functional properties of cortactin, together with amplification of chromosome locus 11q13, suggest a link between its overexpression and tumour invasion and/or metastasis. Accordingly, in several animal models ectopic overexpression of cortactin has been shown to accelerate tumour dissemination, and decreased expression of cortactin, by RNA interference, leads to impaired tumour cell migration and metastasis (Li et al., 2001; Chuma et al., 2004; Hill et al., 2006; Luo et al., 2006).

A growing list of cortactin-binding partners has been identified, including proteins that regulate receptor clustering, endocytosis, and vesicle transport such as dynamin 2 (McNiven et al., 2000) and CD2AP (CIN85-related protein) (Lynch et al., 2003). Recent results from studies in cultured cells (Lynch et al., 2003; Timpson et al., 2005) indicate that cortactin could participate in receptor-mediated endocytosis of the epidermal growth factor (EGF) receptor (EGFR). Thus, cortactin overexpression attenuated ligand-induced down-regulation of EGFR and led to sustained activation of EGFR signalling. Conversely, reduction of cortactin expression in an 11q13-amplified HNSCC cell line by RNA interference accelerated EGFR degradation (Timpson et al., 2005). On the basis of these findings, it was proposed that overexpression of cortactin may contribute to increased EGFR expression and signalling in malignancies with CTTN amplification. This is of particular importance in HNSCC, since enhanced EGFR signalling/expression has been associated with aggressive disease and poor prognosis (Dassonville et al., 1993; Grandis and Tweedale, 1993; Kalyankrishna and Grandis, 2006) and EGFR-targeted molecular therapeutics are currently being examined in clinical settings (for recent reviews, see Astsaturov et al., 2006a, 2006b and Reuter et al., 2007).

To determine whether cortactin expression could be an independent prognostic factor in HNSCC, we have investigated expression of the protein in a large series of HNSCCs using tissue microarray (TMA) technology and have correlated this expression to the outcome of these patients. Epidermal growth factor receptor staining was performed to investigate the potential linkage between cortactin and EGFR overexpression.

MATERIALS AND METHODS

Patient selection

Surgically removed tumours embedded in paraffin wax blocks from 176 cases of HNSCCs were retrieved from the archives of the Department of Pathology (Pasteur Hospital) at the University of Nice, Nice, France. The cases, received between 1993 and 2001, included squamous cell carcinomas exclusively from patients without metastases; basaloid type carcinoma and other nonmucosal tumours were excluded. Cases were selected to build TMAs and included in this study only if a follow-up of at least 5 years was obtained, and clinical data were available. Mean age at surgery was 63 years (range: 37–82) and 138 patients were male. Selected patients displayed similar health status and absence of concurrent chronic illnesses, or tumours elsewhere. The primary sites of the carcinomas were oral cavity (n = 40), pharynx (n = 57; including oropharynx, n = 31 and hypopharynx, n = 26), and larynx (n = 79).

Tumour size according to the TNM classification was T1 (n = 34), T2 (n = 44), T3 (n = 48), and T4 (n = 50). Eighty-seven per cent of the carcinomas were keratinising, with a range of grades: grade I (n = 27), grade II (n = 94), and grade III (n = 55).

Tissue microarray construction

Tissue microarray construction and high-throughput analysis of tissue samples were performed in accordance with Institutional Guidelines. Haematoxylin and eosin-stained sections of primary tumours were reviewed, and areas of tumour and normal tissue were marked on the slides. Areas of necrosis and keratin pools were avoided. Representative carcinoma areas were selected for building TMAs and arrays were designed as previously described (Hoos and Gordon-Cardo, 2001). Briefly, three tissue cores (600 μm in diameter) corresponding to three representative central areas of the tumour were selected. The tissue cores were arrayed into a recipient paraffin block using a fine steel needle and an automatic tissue microarrayer (Beecher Instruments, Sun Prairie, WI, USA and Alphelys, Paris, France). Tissue microarrays of primary carcinomas contained normal tissue adjacent to benign oral tumours from patients (six tissue cores from biopsies performed on these patients), who served as control and for regulating mark spacing from studies in cultured cells (Lynch et al., 2003; Timpson et al., 2005) indicate that cortactin could participate in receptor-mediated endocytosis of the epidermal growth factor (EGF) receptor (EGFR). Thus, cortactin overexpression attenuated ligand-induced down-regulation of EGFR and led to sustained activation of EGFR signalling. Conversely, reduction of cortactin expression in an 11q13-amplified HNSCC cell line by RNA interference accelerated EGFR degradation (Timpson et al., 2005). On the basis of these findings, it was proposed that overexpression of cortactin may contribute to increased EGFR expression and signalling in malignancies with CTTN amplification. This is of particular importance in HNSCC, since enhanced EGFR signalling/expression has been associated with aggressive disease and poor prognosis (Dassonville et al., 1993; Grandis and Tweedale, 1993; Kalyankrishna and Grandis, 2006) and EGFR-targeted molecular therapeutics are currently being examined in clinical settings (for recent reviews, see Astsaturov et al., 2006a, 2006b and Reuter et al., 2007).

To determine whether cortactin expression could be an independent prognostic factor in HNSCC, we have investigated expression of the protein in a large series of HNSCCs using tissue microarray (TMA) technology and have correlated this expression to the outcome of these patients. Epidermal growth factor receptor staining was performed to investigate the potential linkage between cortactin and EGFR overexpression.

Immunohistochemistry

Immunohistochemical methods were performed on serial 2 μm deparaffinized TMA sections. For cortactin detection, intrinsic peroxidase was blocked by incubating sections with 3% hydrogen peroxide for 6 min. Sections were blocked in 4% goat serum for 20 min, then incubated for 30 min with mouse monoclonal anticortactin antibody (clone 4F11; Upstate, Lake Placid, NY, USA and Euromedx, Souffleweyersheim, France). After rinsing with PBS, sections were incubated with biotinylated secondary antibody for 20 min, rinsed with PBS, and incubated with anti-mouse Ig’s streptavidin complexed with biotinylated peroxidase (StreptAB-Complex/HRP; DAKO Corp., Carpinteria, CA, USA) for 20 min. Sections were then washed with distilled water, incubated with developing solution (3-aminio-9-ethylcarbazole; DAKO), counterstained with haematoxylin, and mounted with aqueous mounting medium. Epidermal growth factor receptor was detected on sequential sections using the Invitrogen immunodetection kit (mouse anti-EGFR clone 31G7), as indicated by the manufacturer. After staining, slides were analysed with an image-analysis workstation (Spot Browser version 7; Alphelys), as previously described (Pages et al., 2005). Signal intensity of digitised images was determined using the Spot Browser software; grey values (0 = black to 255 = white) ranged between 102 and 142, and a value inferior or equal to 120 was defined as overexpression. In parallel, staining of the cores was scored by pathologists based on signal intensity (0–3) and the percentage of positive cells (0 ≤ 10%, 1 = 10–25%, 2 = 25–50%, and 3 ≥ 50%). Overexpression of cortactin and EGFR was arbitrarily defined as more than 50% of cells strongly (score 3) stained. Input from visual inspection data and detection of events in digitised images was stored in dedicated tables for comparison and statistical analysis. Discrepancies were resolved by three pathologists (CB, VH, and PH) using a multhead microscope. A disc was considered unsuitable for analysis if it was completely absent, it contained no tumour tissue (sampling error), or it contained too few tumour cells (<10%) for analysis (uninformative). For each patient, the mean score of a minimum of two core biopsies was calculated. Whole tissue sections from tumour blocks of a subset of 30 cases were stained and compared by visual inspection with the corresponding TMA discs using the above-mentioned scoring criteria. These cases were selected to include 10 cases of each grade, and clinicopathological data of these cases were very similar to those of the whole series (not shown). Negative controls for staining used in this study were normal oral mucosa for cortactin and normal striated muscle for EGFR.

For figures, polychromatic high-resolution spot images (1392 × 1040 pixels) were obtained using a Leica DMR optical microscope (Leica Microsystems, Rueil-Malmaison, France) equipped with a CoolSNAP EZ cooled charge-coupled device camera (Roper Scientifique, Evry, France).
Statistics
Histospots containing <10% of a tumour were excluded from additional analyses. Disease-free survival, overall survival, and local recurrence were assessed by Kaplan–Meier analysis with log-rank score for determining statistical significance. All survival analyses were performed at 5-year cutoffs. Relative risk was assessed by the univariate and multivariate Cox proportional hazards model. Comparison of cortactin overexpression with the clinical and pathological variables including gender, TNM stage, histological grade, and tumour type (primary vs recurrent) was made using $\chi^2$ analysis. Calculations and analyses were performed with SPSS 11.5 for Windows (SPSS Inc., Chicago, IL, USA) and where appropriate, two-tailed.

Nonparametric correlation (Spearman’s $\rho$ coefficient; SPSS release 12.01) was used to compare data from whole-tissue sections and discs; and to relate the mean scores obtained from four discs to the scores obtained from individual discs, the mean scores of two discs, and the mean scores for three discs. The degree of agreement between data from whole-tissue sections and the mean of four discs was assessed using weighted Cohen’s $\kappa$ coefficient (SAS for Windows, release 8.02). For descriptive purposes, $\kappa < 0.4$ represents poor-to-fair agreement, 0.4–0.6 moderate agreement.

RESULTS
Clinical and pathological variable analysis
One hundred and seventy-six patients who underwent primary surgical resection for HNSCC in the Department of Otorhinolaryngology (CHU of Nice, France) met inclusion criteria to build TMAss. Demographic and clinicopathological variables for the cohort are summarised in Table 1.

Immunohistochemical analysis of cortactin and EGFR expression
Cortactin immunoreactivity in normal epithelial tissue was low to undetectable (Figure 1A–B). Staining was observed in blood vessels of the underlying connective tissue, both in capillary endothelial cells and in $\alpha$-actin-positive smooth muscle cells of larger vessels. Interestingly, the presence of cortactin in endothelial cells and in perivascular cells was often mutually exclusive (data not shown). Epidermal growth factor receptor staining in normal epithelium was intense in the basal and suprabasal proliferative layers and undetectable in the connective tissue and blood vessels (not shown).

Of the HNSCC tumours that met inclusion criteria, all were interpretable for cortactin staining. Tumours displayed one of the three distinct immunostaining phenotypes (Figure 1): intense diffuse membranous and/or cytoplasmic staining (Figure 1C–D), weak cytoplasmic and/or membranous staining (Figure 1E), and absence of staining (Figure 1F). Cortactin overexpression was defined as intense diffuse cytoplasmic and/or plasma membrane staining in >50% of tumour cells. In all, 77 out of 176 tumours were designated as cortactin overexpressors. No staining was observed in any spots stained with the negative control reagent. Comparisons were made between clinical/pathological variables and cortactin status by $\chi^2$ analysis. Cortactin overexpression was significantly associated with higher TNM stage ($P = 0.005$), as 38 out of the 77 cortactin-overexpressing tumours (49%) were stage IV, as compared with 50 out of the total 176 tumours analysed (28%). Cortactin overexpression was also associated with higher histological grade as 44 out of 77 cortactin-overexpressing tumours were poorly differentiated ($P = 0.001$). There was no association between cortactin status and the other clinical/pathological variables indicated in Table 1. In particular, no association between cortactin status and primary tumour site (oral cavity, oropharynx or hypopharynx, and larynx) was noted.

Epidermal growth factor receptor overexpression is known to be associated with advanced TNM stage, higher histologic grade, and recurrent head and neck tumours (see Dei Tos and Ellis, 2005). This was confirmed for the present cohort by analysis of EGFR expression, as summarised in Table 1. To examine the possible association between the pattern of EGFR expression and cortactin status, a pairwise analysis was performed. Interestingly, none of the tumour specimens with low cortactin levels (cortactin nonoverexpressors) overexpressed the EGFR. Tumours that overexpressed the EGFR were largely positive for EGFR (Figure 2A–B). However, in our series we identified a group of 29 tumours with intense cortactin expression in which the EGFR was not overexpressed (Figure 2C–D). These include 10 T1, 9 T2, and 9 T3 (all N0M0) tumours. Ten of these tumours were well differentiated and 19 tumours were moderately or poorly differentiated.

Importantly, cortactin and EGFR expression levels observed in the TMA discs faithfully reflected the staining intensity of these proteins in whole-tissue sections from corresponding tumour blocks in a subset of 30 cases (see Materials and Methods section).

Survival analysis
Local recurrence The expression status of cortactin, as determined by immunohistochemistry, was evaluated for association with local recurrence using Kaplan–Meier survival analysis with log-rank statistics for determining significance. This analysis

| Cortactin status* | EGFR status* |
|-------------------|--------------|
|                   | $n$ | $-$ | $+$ | $P$ | $n$ | $-$ | $+$ | $P$ |
| Patient cohort    |     |     |     |     |     |     |     |     |
| Age (years)       |     |     |     |     |     |     |     |     |
| Interpretable for cortactin | 176 | 99 | 77 |        | 176 | 66 | 110 |        |
| Interpretable for EGFR   |       |   |     |     |       |   |     |     |
| Positive control |     |     |     |     |     |     |     |     |
| Interpretable for cortactin | 7   | 0  | 7   |        | 9   | 2  | 2   |        |
| Noninterpretable    |       |   |     |     |       |   |     |     |
| Noninterpretable     |       |   |     |     |       |   |     |     |
| Gender              |     |     |     |     |     |     |     |     |
| Male                | 138 | 76 | 62 | 0.11 | 138 | 36 | 102 | 0.13 |
| Female              | 38  | 23 | 15 |     | 38  | 30 | 8   |     |
| Site                |     |     |     |     |     |     |     |     |
| Oral cavity        | 40  | 20 | 20 | 0.42 | 40  | 10 | 30  | 0.39 |
| Pharynx            | 57  | 42 | 15 |     | 57  | 21 | 36  | 0.11 |
| Larynx             | 79  | 66 | 13 |     | 79  | 35 | 39  |     |
| TNM stage          |     |     |     |     |     |     |     |     |
| I                  | 34  | 15 | 19 | 0.005 | 34  | 24 | 10  | 0.004*
| II                 | 44  | 19 | 25 |     | 44  | 20 | 24  |     |
| III                | 48  | 15 | 23 |     | 48  | 16 | 32  |     |
| IV                 | 50  | 12 | 38 |     | 50  | 14 | 36  |     |
| Grade              |     |     |     |     |     |     |     |     |
| Well differentiated | 27  | 15 | 12  $0.001^{\#}\text{a}$ | 27  | 16 | 11  $0.001^{\#}$ |
| Moderately differentiated | 94 | 24 | 70 |     | 94  | 34 | 60  |     |
| Poorly differentiated | 55 | 11 | 44  |     | 55  | 11 | 44  |     |

EGFR = epidermal growth factor receptor; TNM = tumour node metastasis.

* Cortactin/EGFR status: (−) = nonoverexpressor; (+) = overexpressor. \#Significant at the 0.01 level.

Table 1 Comparison of cortactin and EGFR status to demographic, clinical, and pathologic data
demonstrated that cortactin overexpression is associated with increased local recurrence rates. Patients with cortactin nonoverexpression have a local recurrence rate of 28%, compared with 49% for cortactin-overexpressing patients (Figure 3A). Among these latter patients with cortactin-overexpressing tumours, no differences relating to the initial treatment (postoperative radiotherapy alone or not, and postoperative chemotherapy plus radiotherapy or not) were noted. Univariate Cox analysis revealed a hazard ratio for cortactin-overexpressing patients of 6.0 ($P = 0.014$).

**Disease-free survival**

Kaplan–Meier survival analysis (Figure 3B) demonstrated that cortactin overexpression is associated with decreased disease-free survival. Patients with cortactin nonoverexpression have a 5-year disease-free survival of 61%, compared with 17% for cortactin overexpression ($P = 0.0040$). Univariate Cox analysis revealed a hazard ratio for cortactin-overexpressing patients of 2.6 ($P = 0.007$).

**Overall survival**

Kaplan–Meier survival analysis (Figure 3C) demonstrated that cortactin overexpression is associated with decreased overall survival. Patients without cortactin overexpression had a 5-year overall survival of 58%, compared with 21% for cortactin overexpression ($P = 0.0170$). Univariate Cox analysis revealed a hazard ratio for cortactin-overexpressing patients of 2.3 ($P = 0.024$).
Figure 2  Epidermal growth factor receptor and cortactin expression in HNSCC. Squamous cell carcinoma demonstrating both strong cortactin (A) and EGFR (B) coexpression. Squamous cell carcinoma demonstrating cortactin overexpression (C) and EGFR nonoverexpression (D). (Scale bar = 200 μm).

Figure 3  Kaplan–Meier estimates of the 5-year local recurrence (A), disease-free survival (B), and overall survival (C), by cortactin status. Cortactin overexpressors had significantly lower disease-free and lower survival rates than nonoverexpressors. Additionally, cortactin overexpressors had higher local recurrence rates than nonoverexpressors. Kaplan–Meier estimates of the 5-year overall survival by both EGFR and cortactin status (D).
Results for univariate survival analysis of local recurrence, disease-free survival, and overall survival are summarised in Table 2. In parallel, the expression status of EGFR was evaluated for association with overall survival. As mentioned above, EGFR overexpression is associated with decreased overall survival. Results for univariate survival analysis of local recurrence, disease-free survival, and overall survival for this cohort are summarised in Table 3. Interestingly, patients with tumours that do not overexpress the EGFR but overexpress cortactin had a 5-year overall survival of 22%, similar to patients with tumours that overexpress both EGFR and cortactin (Figure 3D).

Multivariate analysis

Using the Cox proportional hazards model, we performed multivariate analysis to assess the independent predictive value of cortactin expression for 5-year disease-free survival, overall survival, and local recurrence. The following prognostic variables were also included tumour type (primary vs recurrent), TNM stage, and histologic grade. For disease-free survival, only cortactin expression status remained an independent prognostic factor ($P = 0.01$). For overall survival, both cortactin status and TNM stage were independent prognostic factors ($P = 0.038$ and $0.014$, respectively). The results for the multivariate survival analysis for EGFR are summarised in Table 3.

DISCUSSION

Amplification of the CTNN gene has been linked to poor prognosis in HNSCC (Rodrigo et al, 2000), yet the relationship between cortactin protein levels and prognosis has not been thoroughly investigated to date. Tissue microarrays have previously been shown to represent reliable tools for the identification of cellular and molecular alterations in several tumour types, including HNSCCs (Gomaa et al, 2005). Recently, in a small number of HNSCCs, 11 out of 39 (28%) cases, cortactin overexpression determined by immunohistochemistry correlated with lymph node metastasis and CTNN gene amplification (Rothschild et al, 2006). In the present study of 176 tumours, we found by quantitative immunohistochemical analysis of TMAs, that cortactin expression status in the tumours of patients with HNSCC is a strong independent prognostic factor for local recurrence as well as disease-free and overall survival. Hence, patients with cortactin-overexpressing tumours displayed a five-fold increase in the risk of local recurrence and nearly a three-fold increase in risk of death by any cause. Importantly, cortactin expression status remained an independent prognostic factor in multivariate analysis.

Several gain- and loss-of-function studies over the past few years have convincingly demonstrated the role of cortactin in regulation

### Table 2 Univariate and multivariate Cox regression analyses by cortactin expression levels

| Cortactin status | Mean time to recurrence (months) | Percentage of recurrence (95% confidence interval) | Hazard ratio (95% confidence interval) | $P$ |
|------------------|---------------------------------|---------------------------------------------------|--------------------------------------|-----|
| **Univariate**   |                                 |                                                   |                                      |     |
| Local recurrence |                                 |                                                   |                                      |     |
| Overexpressor    | 32.0                            | 49.1\% (39–66)                                    | 6.032 (1.6–27.1)                     | 0.014|
| Nonoverexpressor | 47.0                            | 28.0\% (16–49)                                    | 0.169 (0.05–0.8)                     |     |
| Disease-free survival |                                 |                                                   |                                      |     |
| Overexpressor    | 22.2                            | 61.5\% (40–81)                                    | 2.586 (1.2–5.9)                      | 0.007|
| Nonoverexpressor | 34.7                            | 17.5\% (11–29)                                    | 0.379 (0.3–0.8)                      |     |
| Overall survival |                                 |                                                   |                                      |     |
| Overexpressor    | 29.2                            | 57.8\% (35–80)                                    | 2.275 (1.2–4.7)                      | 0.024|
| Nonoverexpressor | 42.5                            | 20.9\% (11–30)                                    | 0.425 (0.3–0.9)                      |     |

| Multivariate Variable | Hazard ratio | 95% confidence interval | $P$ |
|-----------------------|--------------|-------------------------|-----|
| Local recurrence      |              |                         |     |
| Tumour type           | 1.675        | 0.8–3.7                 | 0.20|
| TNM stage             | 1.412        | 0.8–2.4                 | 0.20|
| Histologic grade      | 0.965        | 0.6–1.6                 | 0.90|
| Cortactin overexpressor | 5.293      | 1.2–23.6                | 0.029*|
| Disease-free survival |              |                         |     |
| Tumour type           | 1.616        | 0.9–3.0                 | 0.13|
| TNM stage             | 1.453        | 1.0–2.1                 | 0.06|
| Histologic grade      | 1.033        | 0.7–1.5                 | 0.087|
| Cortactin overexpressor | 3.000      | 1.3–7.0                 | 0.010*|
| Overall survival      |              |                         |     |
| Tumour type           | 1.648        | 0.9–3.1                 | 0.12|
| TNM stage             | 1.679        | 1.1–2.5                 | 0.014*|
| Histologic grade      | 0.984        | 0.7–1.5                 | 0.94|
| Cortactin overexpressor | 2.449      | 1.1–5.7                 | 0.038*|

TNM = tumour node metastasis. *Significant at the 0.05 level.
of cell motility and invasion by virtue of its role in actin remodelling, invadopodia formation, adhesion, endocytosis, and regulation of cell–cell junctions (reviewed in Daly, 2004). Although the acquisition of a motile phenotype has conventionally been regarded as a late event in tumour progression, it was recently proposed that aberrant cell motility may, in addition to being essential to tumour invasion and metastatic dissemination, also contribute significantly to rapid tumour growth (Norton and Massague, 2006). Indeed, cortactin overexpression in our study was associated advanced TNM stage and high histologic grade. From the pathologist’s point of view, cortactin overexpression could be a new prognosis marker for HNSCC.

Cortactin is a substrate of c-Src, and activation of Src family tyrosine kinases is known to be critically involved in carcinoma cell migration extracellular matrix degradation and invasive behaviour. In HNSCC cells, c-Src was proposed to be a downstream target of the EGFR, as treatment of cells with the EGFR inhibitor ŽD1839 was found to block activation of the c-Src pathway (Yang et al, 2004). Src family kinases were also shown to be involved in mediating activation of STATs 3 and 5 in concert with the EGFR in HNSCC cells (Xi et al, 2003). This evidence for a functional association between EGFR and Src/cortactin pathways prompted us to examine EGFR levels in our TMAs. In the majority of cases, EGFR overexpression mirrored cortactin overexpression. However, we identified a subset of 29 tumours in which cortactin and EGFR overexpression could be uncoupled. In these tumours, intense cortactin staining occurred in the absence of strong EGFR staining. Interestingly, patients harbouring these tumours displayed a 5-year overall survival rate that was similar to that of patients with tumours that overexpress both EGFR and cortactin (22 vs 19%, respectively). This finding was unexpected in light of recent studies by Timpson et al (2005) suggesting that cortactin overexpression may contribute to EGFR overexpression. In cultured cells, cortactin overexpression inhibited ligand-induced downregulation of the EGFR (Timpson et al, 2005). Although elevated EGFR expression in tumours is usually associated with more aggressive disease and poor clinical prognosis; in some studies EGFR expression was found to have no prognostic significance (see Dei Tos and Ellis, 2005). This may be the case for the subset of cortactin-overexpressing/EGFR-nonoverexpressing tumours that we describe in which activation or overexpression of signalling components downstream of the receptor could influence cell survival and growth. Whereas these patients may not benefit from EGFR-targeting strategies, they could respond to alternate inhibitors such as Src family kinases that are currently undergoing phase I/II evaluations in advanced solid tumours.

Therapies that target the EGFR have generated high hopes for the management of head and neck cancer. Several clinical trials that explore the use of agents directed against the EGFR, alone or together with various combinations of radiation and chemotherapy, and are currently underway. However, as witnessed in various tumour settings, use of such agents is not without undesirable consequences, and treatment can lead to toxicity and acquired drug resistance. Recently, expression of a tumour-specific constitutively active spliced variant of the receptor (EGFRvIII)

| EGFR status | Mean time to recurrence (months) | Percentage of recurrence (95% confidence interval) | Hazard ratio (95% confidence interval) | P |
|----------------|---------------------------------|-----------------------------------------------------|----------------------------------------|---|
| Univariate Local recurrence | | | | |
| Overexpressor | 35.0 | 48.1% (38–64) | 6.112 (1.3–22.1) | 0.011 |
| Nonoverexpressor | 49.0 | 34.0% (30–46) | 0.135 (0.03–0.5) | |
| Disease-free survival | | | | |
| Overexpressor | 24.2 | 59.2% (40–79) | 2.786 (1.3–5.8) | 0.005 |
| Nonoverexpressor | 36.7 | 16% (11–29) | 0.323 (0.3–0.6) | |
| Overall survival | | | | |
| Overexpressor | 26.2 | 55.5% (34–79) | 2.550 (1.2–4.7) | 0.023 |
| Nonoverexpressor | 39.5 | 19.8% (14–30) | 0.398 (0.2–0.8) | |

| Multivariate Variable | Hazard ratio (95% confidence interval) | P |
|----------------------|----------------------------------------|---|
| Local recurrence | | | |
| Tumour type | 1.556 | 0.7–3.5 | — | 0.25 |
| TNM stage | 1.598 | 0.7–2.6 | — | 0.25 |
| Histologic grade | 0.889 | 0.5–1.3 | — | 0.80 |
| EGFR overexpressor | 5.377 | 1.1–20.5 | — | 0.025* |
| Disease-free survival | | | | |
| Tumour type | 1.557 | 0.8–2.8 | — | 0.11 |
| TNM stage | 1.559 | 1.1–2.5 | — | 0.08 |
| Histologic grade | 1.110 | 0.9–1.9 | — | 0.79 |
| EGFR overexpressor | 2.599 | 1.2–6.1 | — | 0.012* |
| Overall survival | | | | |
| Tumour type | 1.559 | 0.8–3.5 | — | 0.15 |
| TNM stage | 1.450 | 1.3–2.7 | — | 0.011* |
| Histologic grade | 0.999 | 0.9–1.8 | — | 0.84 |
| EGFR overexpressor | 2.568 | 1.2–5.9 | — | 0.041* |

EGFR = epidermal growth factor receptor; TNM = tumour node metastasis. *Significant at the 0.05 level.
was detected in 44% of a small cohort of HNSCCs and found to contribute to enhanced growth and resistance to wild-type EGFR-targeting antibodies (Sok et al, 2006). Altogether these events highlight the therapeutic advantage that targeting multiple components of the EGFR/Src/cortactin axis could represent. Interestingly, recent studies in mammary tumour cells by Hashimoto et al (2006) illustrate the role of cortactin itself as a potential therapeutic target. Thus, blocking the interaction of the cortactin SH3 domain with AMAP1/cortactin overexpressed in invasive mammary tumours with a cell-permeable peptide derived from the AMAP1 sequence, or a small-molecule compound, was found to effectively inhibit AMAP1/cortactin binding, and breast cancer invasion and metastasis (Hashimoto et al, 2006). Numerous investigations have addressed genomic alterations that accompany HNSCC using various techniques (e.g., comparative genomic hybridisation, DNA microarrays, and fluorescence in situ hybridisation). Amplification of the 11q13 locus, where CTNN resides, is the most frequent amplification event in HNSCC and may be driven by a set of genes that could cooperatively provide growth or metastatic advantage to cancer cells including CCND1, FGFR4, FGFR3, SHANK2, and PAK1 (see Huang et al, 2002, 2006 and Gibcus et al, 2007). Indeed, recurrent coamplification of the cytoskeleton-associated genes CCTN and SHANK2 with the cell-cycle control gene CCND1 has been observed in oral squamous cell carcinoma (Freier et al, 2006). Future studies are warranted to determine the possible involvement of other gene products of the 11q13 amplicon in HNSCC. For example, both activity and expression of the serine/threonine kinase Pak1, an effector of the Rac and Cdc42 GTPases and potential cortactin accomplice, was found to be elevated in head and neck tumours as compared with adjacent normal tissue biopsy specimens (Yang et al, 2004), although this study was limited to a small number of tumours.

In conclusion, high levels of cortactin protein expression in HNSCC were closely associated with poor prognosis. Although the precise mechanism remains to be elucidated, this finding is important for several reasons. First, it identifies cortactin as a strong, independent prognostic indicator in patients with HNSCC. Second, it identifies the Src substrate, cortactin as a relevant prognostic marker and pertinent molecular target for development of new antitumoral agents and raises the possibility that cortactin status may guide clinicians in tailoring future therapy.

ACKNOWLEDGEMENTS

We thank Christiane Vigneudo for performing the statistical analyses. This study was supported by grants from Cancrobole PACA/INCa (ACI2004) and the Association pour la Recherche contre le Cancer (ARC3128). We acknowledge the University of Nice – Sophia Antipolis (BQR 2003) and the Conseil Régional PACA for providing funding for the automatic tissue microarrayer and image acquisition and analysis station.

REFERENCES

Artyom VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC (2006) Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase in invadopodia: defining the stages of invadopodia formation and function. Cancer Res 66: 3034 – 3043

Astsaturov I, Cohen RB, Harari P (2006a) Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther 6: 1179 – 1193

Astsaturov I, Cohen RB, Harari PM (2006b) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 6: 691 – 710

Brookes S, Lammie GA, Schuuring E, de Boer C, Michalides R, Dickson C, Peters G (1993) Amplified region of chromosome band 11q13 in breast carcinoma. Hum Genet 90: 629 – 636

Daly RJ (2004) Cortactin signalling and dynamic actin networks. Biochem J 382: 13 – 25

Dassonneville D, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G (1993) Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873 – 1878

Day GL, Blot WJ (1992) Second primary tumors in patients with oral cancer. Cancer 70: 14 – 19

Dei Tos AP, Ellis I (2005) Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 41: 1383 – 1392

Forastiere A, Koch W, Troatti A, Sidransky D (2001) Head and neck cancer. CA Cancer J Clin 51: 15 – 36

Hashimoto S, Hirose M, Hashimoto A, Morishige M, Yamada A, Hosaka H, Akagi K, Ogawa E, Onyama C, Agatsuma T, Okada M, Kobayashi H, Wada H, Nakano I, Ikegami T, Nakagawa A, Sabe H (2006) Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/ proline interface for prevention of breast cancer invasion and metastasis. Proc Natl Acad Sci USA 103: 7036 – 7041

Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouuhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJ (2006) Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. Oncogene 25: 6079 – 6091

Hoos A, Gordon-Cardo C (2001) Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81: 1331 – 1338

Huang X, Godfrey TE, Gooding WE, McCarty Jr KS, Gollin SM (2006) Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and syntenity to the 7F5 amplicon in murine oral carcinoma. Genes Chromosomes Cancer 45: 1058 – 1069

Huang X, Gollin SM, Raja S, Godfrey TE (2002) High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci USA 99: 11369 – 11374

Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666 – 2672

Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M, Zhan X (2001) Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 61: 6906 – 6911

Luo ML, Shen XM, Zhang Y, Wei F, Xu X, Cai Y, Zhang X, Sun YT, Zhan QM, Wu M, Wang MR (2006) Amplification and overexpression of CTNN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 66: 11690 – 11699
Lynch DK, Winata SC, Lyons RJ, Hughes WE, Lehrbach GM, Wasinger V, Corthals G, Cordwell S, Daly RJ (2003) A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem 278: 21805 – 21813

McNiven MA, Kim L, Krueger EW, Orth JD, Cao H, Wong TW (2000) Regulated interactions between dynamin and the actin-binding protein cortactin modulate cell shape. J Cell Biol 151: 187 – 198

Norton L, Massague J (2006) Is cancer a disease of self-seeding? Nat Med 12: 875 – 878

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirillovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654 – 2666

Reuter CW, Morgan MA, Eckardt A (2007) Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96: 408 – 416

Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C (2000) EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 6: 3177 – 3182

Rothschild BL, Shim AH, Ammer AG, Kelley LC, Irby KB, Head JA, Chen L, Varella-Garcia M, Sacks PG, Frederick B, Raben D, Weed SA (2006) Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 66: 8017 – 8025

Schooring E (1995) The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes – a review. Gene 159: 83 – 96

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064 – 5073

Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ (2005) Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res 65: 3273 – 3280

Weed SA, Parsons JT (2001) Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 20: 6418 – 6434

Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, Kamens J, Grandis JR (2003) Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 278: 31574 – 31583

Yamaguchi H, Condeelis J (2007) Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 1773: 642 – 652

Yamaguchi H, Pixley F, Condeelis J (2006) Invadopodia and podosomes in tumor invasion. Eur J Cell Biol 85: 213 – 218

Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R (2004) The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10: 658 – 667